Edition:
United States

OPKO Health Inc (OPK.O)

OPK.O on Nasdaq

6.52USD
22 May 2017
Change (% chg)

-- (--)
Prev Close
$6.52
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
4,409,400
52-wk High
$12.15
52-wk Low
$6.37

Latest Key Developments (Source: Significant Developments)

Xenetic Biosciences reports Q1 loss per share $0.34
Tuesday, 16 May 2017 07:00am EDT 

May 16 (Reuters) - Xenetic Biosciences Inc -:Xenetic Biosciences reports 2017 first quarter financial results and provides business update.Xenetic Biosciences -on track to commence patient recruitment for lead product candidate xbio-101 for treatment of progestin resistant endometrial cancer.Xenetic Biosciences Inc qtrly loss per share $0.34.  Full Article

Opko Health reports quarterly loss per share $0.06
Tuesday, 9 May 2017 04:10pm EDT 

May 9 (Reuters) - Opko Health Inc ::Opko Health reports 2017 financial and operating results.Q4 revenue $296.1 million versus I/B/E/S view $310.8 million.Quarterly loss per share $0.06.  Full Article

Opko Health CEO reports purchase of 10,000 shares of co's common stock on May 5
Monday, 8 May 2017 07:01am EDT 

May 8 (Reuters) - Opko Health Inc :Opko Health Inc <<>> CEO Phillip Frost reports purchase of 10,000 shares of co's common stock on May 5 - SEC filing.  Full Article

CEO Phillip Frost reports purchase of 12,200 shares of common stock of Opko Health Inc
Friday, 24 Mar 2017 07:34am EDT 

Opko Health Inc :CEO Phillip Frost reports purchase of 12,200 shares of common stock of Opko Health Inc as of March 23.  Full Article

OPKO receives FDA orphan drug status to treat genetic neurological disorder
Wednesday, 22 Mar 2017 08:00am EDT 

OPKO Health Inc - : OPKO receives FDA orphan drug status for its new oligonucleotide to treat genetic neurological disorder . OPKO Health Inc says OPKO plans to initiate a clinical trial of cur-1916 for treatment of dravet syndrome this year .Received orphan drug designation from U.S. FDA for oligonucleotide-based antagonat (cur-1916) for treatment of dravet syndrome.  Full Article

Opko Health says plans to initiate a clinical trial of CUR-1916
Wednesday, 8 Mar 2017 08:00am EST 

Opko Health Inc : Opko receives EU orphan drug status for its new oligonucleotide to treat genetic neurological disorder .Opko Health Inc - Opko plans to initiate a clinical trial of CUR-1916 for treatment of dravet syndrome this year.  Full Article

OPKO Health Qtrly diluted loss per share $0.04
Wednesday, 1 Mar 2017 04:13pm EST 

Opko Health Inc : OPKO Health reports 2016 financial and operating results . Q4 revenue $275.5 million versus i/b/e/s view $310.8 million . Qtrly diluted loss per share $0.04 .Q4 earnings per share view $-0.04 -- Thomson Reuters I/B/E/S.  Full Article

Opko Health CEO Phillip Frost reports purchase of 8,600 shares of co's common stock on Jan 20
Monday, 23 Jan 2017 06:46am EST 

Opko Health Inc :Opko Health Inc CEO Phillip Frost reports purchase of 8,600 shares of Co's common stock on Jan 20 - sec filing.  Full Article

Opko Health qtrly diluted income per share $0.02
Monday, 8 Aug 2016 04:05pm EDT 

Opko Health Inc : Opko health reports improved financial and operating results . Qtrly diluted income per share $ 0.02 .Qtrly total revenue $357.1 million versus $42.4 million.  Full Article

Opko Health says Transition Therapeutics will pay co fee of $3 mln if deal is terminated -SEC filing
Thursday, 30 Jun 2016 10:17am EDT 

Opko Health : If agreement is terminated under certain circumstances Transition Therapeutics will be required to pay co termination fee of $3 million Source: (http://1.usa.gov/29cpxUH ) Further company coverage: [OPK.O] (Bengaluru Newsroom: +1 646 223 8780).  Full Article

More From Around the Web

BRIEF-Opko Health reports 5.11 pct Passive Stake in Rxi Pharmaceuticals

* Opko Health reports 5.11 pct passive stake in RXi Pharmaceuticals Corp as of Dec 21, 2016 - SEC filing Source text: (http://bit.ly/2jJqgB2) Further company coverage: